Forget Centessa Pharmaceuticals: This Rare-Disease Specialist Has a Superior Portfolio and Pipeline [Yahoo! Finance]
Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Company Research
Source: Yahoo! Finance
Over the past year, shares of Centessa Pharmaceuticals (NASDAQ: CNTA) have significantly outperformed broader equities as the biotech has made tremendous progress with a promising pipeline candidate. However, it's worth wondering whether the drugmaker still has significant upside left after this run. Maybe it does, but before buying shares of Centessa, investors should consider another larger, well-established biotech with (arguably) much better prospects: Vertex Pharmaceuticals (NASDAQ: VRTX) Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Image source: Getty Images. Centessa's strengths and weaknesses Centessa Pharmaceuticals is developing a medicine called ORX750 for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). ORX750 is an orexin receptor agonist -- that is, it mi
Show less
Read more
Impact Snapshot
Event Time:
CNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTA alerts
High impacting Centessa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CNTA
News
- Centessa Pharmaceuticals (CNTA) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Centessa Pharmaceuticals (NASDAQ:CNTA) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $40.00 price target on the stock.MarketBeat
- Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
- Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Truist Financial Corporation from $33.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Centessa Pharmaceuticals (NASDAQ:CNTA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
CNTA
Earnings
- 8/12/25 - Miss
CNTA
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/13/26 - Form 8-K
- 2/6/26 - Form SCHEDULE
- CNTA's page on the SEC website